2020
A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL
Li X, Jemaa S, Carano R, Bengtsson T, Paulson J, Jansen G, Nielsen T, Hibar D. A Prognostic Model Incorporating Tumor Lesion Morphology and Texture Features Identifies High-Risk Patient Subpopulations in De Novo DLBCL and FL. Blood 2020, 136: 28. DOI: 10.1182/blood-2020-134877.Peer-Reviewed Original ResearchDiffuse large B-cell lymphomaProgression-free survivalCurrent equity holderInternational Prognostic IndexFDG-PET scansProgression-free survival probabilityLow-risk groupHigh-risk groupBaseline FDG-PET scanHigh-risk patientsPredicting high-risk patientsFollicular lymphomaFL patientsPrognostic performanceF. Hoffmann-La RocheRadiomic featuresCHOP chemotherapyGALLIUM studyStratify patientsDe novo diffuse large B-cell lymphomaDLBCL populationDiffuse large B-cell lymphoma patientsHigh-risk patient subpopulationsInternational Prognostic Index modelLarge B-cell lymphoma
2019
Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL
Kim E, Fan J, Bolen C, Bazeos A, Jiang Y, Balasubramanian S, Balakrishnan R, Knapp A, Humphrey K, Nielsen T, Venstrom J, Hernandez G, Paulson J. Recapitulation of Prognostic Mutational Subtyping Utilizing F1H in GOYA and CAVALLI and the Potential to Highlight Benefit of Targeted Therapy in De Novo DLBCL. Blood 2019, 134: 2788. DOI: 10.1182/blood-2019-124687.Peer-Reviewed Original ResearchWhole-exome sequencingDiffuse large B-cell lymphomaExome-sequencing dataInternational Prognostic IndexBCL2 inhibitor venetoclaxHigh-risk groupRNA gene expression dataGene expression dataTargeted therapyClinical outcomesCopy number amplificationNext-generation sequencingDe novo diffuse large B-cell lymphomaAssociated with inferior clinical outcomesLarge B-cell lymphomaGenetic risk modelsNucleotide variantsAdverse prognostic impactClinical prognostic scoresB-cell lymphomaInferior clinical outcomesImprove survival outcomesExpression dataExome sequencingClinically heterogeneous disease